<DOC>
	<DOCNO>NCT00056862</DOCNO>
	<brief_summary>This study examine effectiveness low-dose peginterferon ribavirin therapy certain patient chronic hepatitis C-a liver disease , patient , progress cirrhosis liver , liver cancer , liver failure .</brief_summary>
	<brief_title>Low-Dose Peginterferon Ribavirin Treat Chronic Hepatitis C Patients Infected With HCV Genotype 2 3</brief_title>
	<detailed_description>Sixty patient chronic hepatitis C infect HCV genotype 2 3 treat use combination either low- standard dose peginterferon ribavirin 24 week , re-treatment use standard dos long duration ( 48 week ) respond relapse initial low dose therapy . Adult patient chronic hepatitis C HCV genotype 2 3 previously receive anti-viral treatment give peginterferon alfa-2a ( 90 180 microgram weekly injection ) ribavirin ( 800 mg daily mouth ) . Patients monitor 2- 4-week interval side effect , compliance , complete blood count , liver biochemical test HCV RNA . Patients become HCV RNA negative week 12 consider on-treatment responder , continue therapy week 24 , monitor thereafter another 24 week . Patients become HCV RNA negative week 12 well patient relapse therapy retreat 180 microgram peginterferon weekly 800 mg ribavirin another 48 week . The primary outcome sustain loss HCV RNA 24 week low- standard-dose combination therapy . Secondary outcome include viral kinetics side effect . Because preliminary result initial 31 patient enrol study , dose peginterferon change 90 180 microgram weekly remain 29 patient enrol , allow direct comparison efficacy , viral kinetics side effect standard- vs low-dose peginterferon therapy . This study evaluate relative efficacy safety standard versus low dos peginterferon ribavirin patient chronic hepatitis C HCV genotype 2 3 .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>INCLUSION CRITERIA : Age 18 year , male female . Presence antiHCV serum . Positive HCV RNA determination serum . HCV genotype 2 3 determine Inno LiPa assay direct sequencing . Patients mixed genotype eligible genotype 2 3 . Written informed consent . EXCLUSION CRITERIA : Previous treatment interferon alpha peginterferon . Decompensated liver disease , mark bilirubin great 4 mg/dL , albumin less 3.0 g/dL , prothrombin time great 2 sec prolong , history bleed esophageal varix , ascites hepatic encephalopathy . Patients ALT level great 1000 U/L ( great 25 time ULN ) enrol may follow three determination level . Pregnancy , woman childbearing potential spouse woman , inability practice adequate contraception , define vasectomy men , tubal ligation woman , use condom spermicidal , birth control pill , intrauterine device . Significant systemic major illness liver disease , include congestive heart failure , renal failure ( creatinine clearance le 50 ml/min ) , organ transplantation , serious psychiatric disease control psychotropic agent , angina pectoris . Evidence coronary artery disease cerebral vascular disease , include abnormality exercise stress test patient define risk factor screen evidence underlie coronary artery disease . Preexisting , severe bone marrow compromise ; anemia ( hematocrit le 30 % ) , neutropenia ( less 1000 neutrophils/microliter ) thrombocytopenia ( le 70,000 cells/microliter ) . History hemolytic anemia . Evidence another form liver disease addition hepatitis C ( example hepatitis B , autoimmune liver disease , Wilson 's disease , alcoholic liver disease ) . Active substance abuse , alcohol , inhale injection drug within previous six month . Evidence hepatocellular carcinoma : either alfafetoprotein ( AFP ) level great 50 ng/ml ( normal less 9 ng/ml ) and/or ultrasound ( image study ) demonstrate mass suggestive liver cancer . Clinical gout . HIV infection . Quiescent active , serious autoimmune disease lupus erythematosus , ulcerative colitis , Crohn 's disease rheumatoid arthritis opinion investigator might exacerbate therapy alfa interferon . The use immunosuppressive medication , include corticosteroid dose 10 mg prednisone equivalent high .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Hepatitis C Virus</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Hemolysis</keyword>
	<keyword>Neutropenia</keyword>
	<keyword>Cirrhosis</keyword>
	<keyword>Hemolytic Anemia</keyword>
	<keyword>Viral Hepatitis</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Alfa Interferon</keyword>
	<keyword>Pegylated Interferon</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV</keyword>
</DOC>